Core Laboratories NV (CLB) financial statements
Core Laboratories NV reported revenue of $527M in fiscal 2025, up 2.9% a year over 4 years.
Net income was $30M and the operating margin 10.7%, against 9.6% in 2021.
Free cash flow was $26M, and the company returned $2M in dividends and $12M in net buybacks.
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Core Laboratories NV's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $470M | $490M | $510M | $524M | $527M |
| Cost of revenue | — | $394M | $400M | $421M | $418M |
| Selling, general and admin | — | $38M | $40M | $40M | $45M |
| Operating income | $45M | $42M | $55M | $59M | $56M |
| Interest expense | $9M | $12M | $13M | $12M | $11M |
| Pre-tax income | $36M | $30M | $41M | $46M | $46M |
| Income tax | $16M | $10M | $4M | $14M | $16M |
| Net income | $20M | $19M | $37M | $31M | $30M |
| EPS (diluted) | $0.42 | $0.42 | $0.77 | $0.66 | $0.63 |
| Diluted shares | 46M | 46M | 47M | 47M | 46M |
| Operating margin | 9.6% | 8.5% | 10.7% | 11.2% | 10.7% |
| Net margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
Balance sheet
Fiscal years, from Core Laboratories NV's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and short-term investments | $18M | $15M | $15M | $19M | $23M |
| Receivables | — | $107M | $109M | $112M | $114M |
| Inventory | — | $60M | $72M | $59M | $54M |
| Total current assets | — | $212M | $223M | $221M | $215M |
| Property, plant and equipment | $111M | $105M | $100M | $97M | $99M |
| Goodwill | — | $99M | $99M | $99M | $106M |
| Total assets | $581M | $578M | $586M | $585M | $584M |
| Total current liabilities | — | $103M | $88M | $102M | $106M |
| Long-term debt | — | $172M | $163M | $126M | $110M |
| Total liabilities | — | $395M | $362M | $333M | $312M |
| Shareholders' equity | $161M | $184M | $225M | $247M | $266M |
| Net debt | -$18M | $157M | $148M | $107M | $88M |
Cash flow
Fiscal years, from Core Laboratories NV's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $37M | $25M | $25M | $56M | $37M |
| Capital spending | $14M | $10M | $11M | $12M | $11M |
| Free cash flow | $23M | $15M | $14M | $44M | $26M |
| Stock-based compensation | $19M | $8M | $14M | $4M | $7M |
| Dividends paid | $2M | $2M | $2M | $2M | $2M |
| Share buybacks (net) | -$8M | -$4M | -$2M | -$5M | -$12M |
| Net borrowing | -$71M | -$15M | -$9M | -$38M | -$15M |
| Free cash flow margin | 4.9% | 3.0% | 2.8% | 8.5% | 4.9% |
| Dividends per share | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CLB.
Open CLB in InvestinglyQuestions
What was Core Laboratories NV's revenue in 2025?
$527M in fiscal 2025, from its 10-K filing.
How much free cash flow does Core Laboratories NV generate?
$26M in fiscal 2025 (operating cash flow minus capital spending).
From Core Laboratories NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.